GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (OTCPK:MYCOF) » Definitions » Selling, General, & Admin. Expense

Mydecine Innovations Group (Mydecine Innovations Group) Selling, General, & Admin. Expense : $11.92 Mil (TTM As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Mydecine Innovations Group Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Mydecine Innovations Group's selling, general, & admin. expense for the three months ended in Sep. 2023 was $5.19 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Sep. 2023 was $11.92 Mil.


Mydecine Innovations Group Selling, General, & Admin. Expense Historical Data

The historical data trend for Mydecine Innovations Group's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Selling, General, & Admin. Expense Chart

Mydecine Innovations Group Annual Data
Trend Dec13 Aug14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.95 2.43 5.75 10.80 7.23

Mydecine Innovations Group Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 2.99 2.08 1.66 5.19

Competitive Comparison of Mydecine Innovations Group's Selling, General, & Admin. Expense

For the Drug Manufacturers - Specialty & Generic subindustry, Mydecine Innovations Group's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mydecine Innovations Group's Selling, General, & Admin. Expense Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mydecine Innovations Group's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Mydecine Innovations Group's Selling, General, & Admin. Expense falls into.



Mydecine Innovations Group Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mydecine Innovations Group  (OTCPK:MYCOF) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Mydecine Innovations Group Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Mydecine Innovations Group's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Mydecine Innovations Group (Mydecine Innovations Group) Business Description

Traded in Other Exchanges
Address
789 West Pender Street, Suite 810, Vancouver, BC, CAN, V6C 1H2
Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group (Mydecine Innovations Group) Headlines

From GuruFocus

Mydecine Announces Change of Auditor

By Business Wire Business Wire 01-22-2021

Mydecine Innovations Group Upsizes Previously Announced Bought Deal

By Business Wire Business Wire 01-20-2021